The Hindu·2 min read·medium
Natco Pharma gets USFDA nod for generic cancer drug, shares rise 4% intra-day
T
The Hindu Bureau
✦AI Summary
Natco Pharma shares rose after receiving tentative U.S. FDA approval for a generic version of the cancer drug Lynparza. The company plans to manufacture the drug while partnering with Alembic Pharmaceuticals for distribution.
Hyderabad-based Indian multinational pharmaceutical and biotechnology company Natco Pharma’s shares were in the spotlight on Monday after it received tentative approval from the U.S. Food and Drug Administration (FDA) for Olaparib, 100 mg, and 150 mg, which are bioequivalent to AstraZeneca Pharmaceuticals’ referenced drug Lynparza used in the treatment of certain types of cancer.
businesshealth
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in